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Abstract
Background Policymakers need to know the cost-effec-
tiveness of interventions to prevent type 2 diabetes (T2D).
The objective of this study was to estimate the cost-ef-
fectiveness of a T2D prevention initiative targeting weight
reduction, increased physical activity and healthier diet in
persons in pre-diabetic states by comparing a hypothetical
intervention versus no intervention in a Swedish setting.
Methods A Markov model was used to study the cost-ef-
fectiveness of a T2D prevention program based on lifestyle
change versus a control group where no prevention was
applied. Analyses were done deterministically and proba-
bilistically based on Monte Carlo simulation for six dif-
ferent scenarios defined by sex and age groups (30, 50,
70 years). Cost and quality adjusted life year (QALY)
differences between no intervention and intervention and
incremental cost-effectiveness ratios (ICERs) were esti-
mated and visualized in cost-effectiveness planes (CE
planes) and cost-effectiveness acceptability curves (CEA
curves).
Results All ICERs were cost-effective and ranged from
3833 €/QALY gained (women, 30 years) to 9215 €/QALY
gained (men, 70 years). The CEA curves showed that the
probability of the intervention being cost-effective at the
threshold value of 50,000 € per QALY gained was very
high for all scenarios ranging from 85.0 to 91.1%.
Discussion/conclusion The prevention or the delay of the
onset of T2D is feasible and cost-effective. A small
investment in healthy lifestyle with change in physical
activity and diet together with weight loss are very likely to
be cost-effective.
Keywords Markov model  Cost-effectiveness  Diabetes 
Prevention  Lifestyle change
JEL Classification I1 (Health)
Background
Diabetes
Diabetes poses a huge burden on society both in human
suffering and health expenditure terms. Diabetes is a
common and costly disease that is expected to even con-
tinue to grow in prevalence and health expenditures over
the coming decades. The International Diabetes Federation
(IDF) estimated that approximately 52 million adults
(20–79 years of age) had diabetes in the IDF EUR Region
with a prevalence of 7.9% in 2014 [1]. In Sweden, the
estimated number of cases was 426,800 among adults in
2014, amounting to a prevalence of 6.1% [1]. The number
of diabetes-related deaths among Swedish adults was
estimated at 2930 while the cost per person with diabetes in
Sweden was 6310 USD [1]. It is estimated that incidence
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and prevalence of diabetes and consequently its costs in
Sweden and Europe will increase in the future making
prevention initiatives essential. An epidemiological model
based on German data confirmed that unless enormous
efforts are conducted into prevention programs, the number
of persons with diabetes are expected to increase in the
next two decades [2].
The three main types of diabetes are gestational dia-
betes, type 1 diabetes and type 2 diabetes (T2D); we focus
on T2D in this analysis. T2D is the most common diabetes
type and is characterized by insulin resistance and relative
insulin deficiency. T2D develops over a long time period
and is often undetected over years. During this time, people
almost always first develop any of the pre-diabetic states,
i.e., impaired fasting glucose (IFG), impaired glucose tol-
erance (IGT) or a combination of both (IFG and IGT). IFG
is largely associated with an impaired insulin secretion and
impaired suppression of hepatic glucose output, while IGT
is mainly associated with muscle insulin resistance and
defective insulin secretion [3].
Markov models and diabetes prevention
Markov models are used to estimate future costs and
effects of treatment options. They extrapolate current
knowledge to be able to make decisions that have impacts
on the future. Markov models may help to optimize the
selection of individuals eligible for a focused intervention,
such as specific lifestyle interventions [4].
Several trials have shown that prevention of T2D among
individuals at high risk through lifestyle change is possible,
effective and cost-effective, especially targeting diet and
exercise to reduce weight [5–11]. Lifestyle modification is
considered the first choice of intervention for T2D pre-
vention as it has a good cost- and treatment-effectiveness
[12]. However, the long-term cost-effectiveness of a life-
style intervention program in a Swedish setting is still not
clear. On the other hand, policymakers need to know the
cost-effectiveness of interventions to prevent T2D before
implementing them at population level [13].
Various studies have estimated the effectiveness and
cost-effectiveness of T2D prevention initiatives starting in
the increased risk state IGT [14–18]. Some studies focused
on the effect of screening for T2D [18, 19]. Other studies
have investigated the cost-effectiveness of healthy indi-
viduals (NGT) but only IGT as pre-diabetic state [20, 21].
However, no study to our knowledge has estimated the
cost-effectiveness of T2D prevention strategies from a
population-based perspective, including healthy individu-
als and also considering IFG and IGT as two distinct pre-
diabetic states. Previous research has, nonetheless, shown
that IFG and IGT are different regarding risk of developing
a worsened health state and quality of life [22–25]. Norris
and colleagues consequently underlined that further
research is needed to define the duration of the pre-diabetes
phase and to identify measurable risk factors for progres-
sion to T2D and its complications [26].
Objective
The objective of this study was to estimate the cost-ef-
fectiveness of a T2D prevention initiative targeting weight
reduction, increased physical activity and healthier diet in
persons in pre-diabetic states by comparing a hypothetical
intervention comparable to the Finish Diabetes Prevention
Study (DPS) versus no intervention in a Swedish setting.
Methods
A Markov model was used to study the cost-effectiveness
of a hypothetical T2D prevention program based on life-
style change through increased physical activity, healthier
diet and weight reduction versus a control group where no
prevention was applied. The hypothetical intervention is
based on results by other T2D prevention programs tar-
geting lifestyle change, including identification of indi-
viduals at higher risk, offering an educational course and
follow-up mentoring and visits [5, 6, 20, 27, 28].
The model
The model consisted of six different, mutually exclusive
states (Fig. 1). The states described the possible develop-
ment of T2D through a simulation of hypothetical persons
using average values of input parameters in combination
with assumed distributions. The Markov model is charac-
terized by a population with mean values for risk factors
that are adjusted by the intervention effect.
A hypothetical person in a healthy state, NGT, could
develop IFG, IGT or IFG and IGT, the pre-diabetic states.
From any of the pre-diabetic states, the person could
develop T2D. In return, a person with T2D could move to a
pre-diabetic state or they could move from a pre-diabetic
state to NGT. Direct changes between the pre-diabetic
states were not possible in the model. Even though such
changes are plausible, they have not been estimated in this
model for simplicity reasons and because the available
number of individuals for estimating the risk equation was
not sufficient to build robust estimates stratified by risk
factors.
The transition to move back from T2D to any pre-dia-
betic state was kept in the model, even though a person
who once entered the T2D state is not comparable with the
one who never had T2D. On the other hand, this change is
possible and lifestyle interventions could have an impact
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on this transition. In addition, some people who had once
been diagnosed with T2D might attain healthy values and
will not have the same costs and complications as an
average person with T2D.
At any time, the person could die and consequently
move to the absorbing state death.
The length of one cycle was 1 year. A lifetime horizon




The risk of moving from one state to another was described
by transition probabilities. The arrows indicated all possi-
ble transitions between the states during a 1-year cycle
length (Fig. 1). As it was assumed that 1 year was too short
to develop T2D directly from NGT, this transition was not
possible. Hence, all hypothetical persons must have
developed any of the three pre-diabetic states before the
development of T2D. The transition probabilities in this
study were extracted from a previous study based on the
Va¨sterbotten Intervention Program (VIP) [22] and they
depend on the following risk factors: sex, age, education,
triglyceride, blood pressure, body mass index (BMI),
smoking, physical activity, snus use, nutrition, marital
status, family history of T2D and self-reported health status
(Table 1). In the model, all those risk factors could be
adjusted according to the lifestyle of the individual. The
transition probabilities were estimated based on the logistic
regression of transitions in the VIP by estimating the risk of
changing to a different glucose state depending on a range
of risk factors [22] (Table 2).
The characteristics of the population without the inter-
vention were based on the distribution of the characteristics in
the VIP population at first examination with any of the pre-
diabetic states [22] (Table 3). The success of the intervention
was defined by changes in three characteristics, i.e., BMI,
physical activity and nutrition, at the starting year: a weight
reduction of 5% [29], an increase in physical activity by 13%
[30] and an increase by 10% of the proportion of individuals
consuming at least five portions of fruits and vegetables per
day [6]. Changes in all three categories are well described as
realistic changes due to lifestyle intervention programs.
Results were stratified by sex and age [younger age
(30 years), middle age (50 years) and older age (70 years)]
at the start of the intervention.
To be conservative, it was assumed that the effectiveness
of the lifestyle program decreased over time. The Finnish
Diabetes Prevention Study (DPS) found that after discon-
tinuation of active counseling, the lifestyle intervention
group still had a lower incidence of T2D after 7 years
compared to the no-intervention group [30]. Consequently,
the effect of the intervention in this model was assumed to
remain for only 7 years with a linear decrease over the
7 years to zero effectiveness in year eight and onwards. This
means that after 7 years, there was no difference in transition
probabilities of intervention versus no intervention. This
assumed effectiveness is conservative, since a study based on
the Diabetes Prevention Program (DPP) in the United States
even estimated that incidence remained lower in the lifestyle
group even after 10 years [27].
As the intervention targets persons at higher risk of
developing T2D, all hypothetical persons start in any of the
pre-diabetic states. In the starting year, 66.2, 27.2 and 6.6%
of the hypothetical persons in the model had IFG, IGT or
IFG and IGT, respectively, based on the distribution of
Fig. 1 Markov model. NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, T2D type 2 diabetes
mellitus
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participants at first examination in the VIP in the years
between 1990 and 1999 [22].
Mortality
Age-based all-cause mortality and mortality due to T2D
(ICD10: E10) in Va¨sterbotten were taken from Statistics
Sweden and the National Board of Health and Welfare
based on the years 2003–2009 [31]. Five-year age ranges
were estimated. The range 2003–2009 was used because
data for transition probabilities were based on data from
1990 to 2009, and data for health utility weights (HUWs,
see below) were based on data from 2003 to 2012. The
overlapping time period is 2003–2009.
No increased risk of dying due to any of the pre-diabetic
states was assumed.





Education High University or education[12 years education
Middle 10–12 years of education
Low Compulsory school or\10 years of education
Triglyceride Normal \1.7 mmol/l
High C1.7 mmol/l
Blood pressure Normal Systolic blood pressure\140 mmHg and diastolic blood pressure\90 mmHg AND no self-reported anti-
hypertensive drug
High Self-reported anti-hypertensive drug OR systolic blood pressure C140 mmHg OR diastolic blood pressure
C90 mmHg









Exercise at least 2–3 times/week or walk and/or cycle more than 3 times/week during leisure time or walk or
cycle to work more than 5 km per way
Moderately
active
Exercise now and then but not regularly or cycle and/or walk during their leisure time at least 2–3 times per
week or cycle and/or walk to work 2–5 km each way
Sedentary Never exercise or walk and/or cycle during their leisure time less than 2–3 times per week or take bus or car
to work or cycle and/or walk to work less than 2 km per way.
Current snus use No Snus is an oral non-smoking tobacco that is commonly used in Sweden. It is put into the mouth, usually




Nutrition At least 5 a
day
At least five portions of fruits/vegetables per day
Less than 5 a
day
Less than five portions of fruits/vegetables per day
Marital status Partnership Married or living with spouse
Single Not married or widowed or divorced
Family history of
T2D
Yes Parents or siblings with T2D
No No parents or sibling with T2D
Self-perceived
health
Good Very good, pretty good, somewhat good
Bad Pretty bad, bad
BMI body mass index, calculation: (weight in kg)/(height in m)
A. Neumann et al.
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Utilities
The self-perceived preference of one state over another is
expressed by health utility weights (HUWs). A person with
a HUW of zero considers his or her wellbeing equivalent to
death while someone with a HUW of one considers his or
her wellbeing equivalent to ‘‘perfect health’’. HUWs were
used to calculate quality adjusted life years (QALYs) by
combining HUWs with the lengths stayed in the state. The
HUWs in this study were based on the VIP population
between the years 2003 and 2012 and were adjustable by
age, sex, education and BMI (Table 1). The HUWs were
derived from the Short-Form 36 (SF-36) questionnaire in
the VIP study and translated to Short-Form 6D (SF-6D)
values [32]. Beta regression was used to estimate HUWs
based on the defined risk factors and stratified by glucose
group [23]. The estimated HUWs with the assumed effects
(Table 2) indicate only minor changes between ages and
sexes (Table 4). HUWs decrease with worsened glucose
state, with the exception of IFG and IGT. Women had
lower HUWs compared to men. Older age (70 years) leads
to a very minor decrease in HUWs, with the exception of
IFG and IGT. As for transition probabilities described
above, the effect of the intervention was assumed to remain
for only 7 years with a linear decrease of the effectiveness
to zero in year eight. This means that after 7 years, there
was no difference in HUWs of intervention versus no
intervention (HUWs not shown).
Costs
Cost for T2D was divided into direct (inpatient care, out-
patient hospital care, outpatient primary care, antidiabetic
drugs, antihypertensive drugs, lipid-lowering drugs, devi-
ces) and indirect (sickness absence, early retirement, pro-
duction loss due to mortality) costs (Table 5) [33, 34]. The
direct annual cost due to T2D in Sweden was estimated at
3602 € [33]. It was estimated that 57% of the total cost was
due to indirect costs [34]. Therefore, the total annual cost
for T2D was estimated at 8376.74 €. Several studies esti-
mated that IGT, IFG and IFG and IGT consume a sub-
stantially higher amount of resources compared to NGT
[35–37]. Palmer and colleagues assumed a cost of 46% of
T2D cost [37]. NGT had no costs associated compared to
the other states.
Intervention cost
The cost for the lifestyle intervention was taken from a
low-intensive population-based intervention in Germany,
the Saxon Diabetes Prevention Program [20]. The inter-
vention consists of three steps, i.e., firstly identifying
Table 2 Risk equations for the change between disease states, adapted from [15]
From state A to
state B
Regression model
NGT to IFG Logit P(NGT to IFG) = –3.07 to 0.29 * sex ? 0.01 * age ? 0.11 * education ? 0.19 * family history of T2D –0.09 *
current snus use ? 0.15 * triglyceride ? 0.12 * blood pressure ? 0.16 * BMI ? 0.23 * smoking
NGT to IGT Logit P(NGT to IGT) = –7.29 ? 0.51 * sex ? 0.06 * age ? 0.09 * education ? 0.14 * physical activity ? 0.15 * family
history of T2D ? 0.41 * triglyceride ? 0.34 * blood pressure ? 0.21 * BMI –0.12 * smoking
NGT to IFG and
IGT
Logit P(NGT to IFG and IGT) = –6.20 to 0.16 * sex ? 0.04 * age –0.24 * current snus use ? 0.32 * family history of
T2D ? 0.15 * physical activity ? 0.20 * triglyceride ? 0.60 * blood pressure ? 0.50 * BMI –0.33 * nutrition
IFG to NGT Logit P(IFG to NGT) = = 2.84–0.43 * family history of T2D –0.02 * age –0.23 education –0.25 * blood pressure –0.38 *
BMI –0.26 * triglyceride
IGT to NGT Logit P(IGT to NGT) = 3.06 ? 0.72 * sex –0.07 * age –0.23 * education –0.37 * BMI –0.29 * self-perceived health –
0.49 * triglyceride
IFG and IGT to
NGT
Logit P(IFG and IGT to NGT) = –0.61 ? 0.81 * sex ? 1.15 * current snus use –1.24 * smoking 1 –0.77 * BMI
IFG to T2D Logit P(IFG to T2D) = –6.98 to 0.44 * sex ? 0.05 * age ? 0.48 * family history of T2D ? 0.36 * marital status ? 0.51
* nutrition ? 0.30 * triglyceride ? 0.61 * blood pressure ? 0.57 * BMI
IGT to T2D Logit P(IGT to T2D) = –6.54 to 0.75 * sex ? 0.07 * age ? 0.87 * nutrition ? 0.35 * BMI ? 0.35 * blood
pressure ? 0.56 * triglyceride
IFG and IGT to
T2D
Logit P(IFG and IGT to T2D) = - 0.55 - 0.61 * sex ? 0.71 * BMI ? 0.87 * family history of T2D - 1.06 *
nutrition ? 0.42 * smoking
T2D to IFG Logit P(T2D to IFG) = –0.34 to 0.57* BMI - 0.68 * blood pressure –0.385 * smoking
T2D to IGT Logit P(T2D to IGT) = –3.37 to 1.42 * family history of T2D ? 1.13 self-perceived health
T2D to IFG and GT Logit P(T2D to IFG and IGT) = –6.80 ? 1.22 * sex ? 1.49 * physical activity ? 0.63 * education –1.07 * self-perceived
health
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individuals at higher risk for developing T2D, secondly
conducting weekly courses for 8 weeks on the physiology
of the body, healthy eating, exercise and motivation guided
by prevention managers and thirdly offering follow-up
mentoring with the prevention manager which continues as
long as the participant wishes. Prevention managers are
individuals trained for motivational counseling and dia-
betes prevention (diet and physical activity). Cost for the
1st year was estimated to be 390.43 €, while cost for years
two to five were 189.93 €. The intervention cost includes
the cost for screening (1st year), a course on healthy life-
style (1st year) and follow-up through trained prevention
managers (2nd to 5th years). The estimations were based
on a cost analysis of the Saxon Diabetes Prevention Pro-
gram from a societal perspective [20]. Costs for the inter-
vention occur only for the first 5 years.
All costs and quality adjusted life years (QALYs) were
discounted at 3% according to the Guidelines of the
International Society for Pharmacoeconomics and Out-
come Research (ISPOR) Sweden [38].
Analyses
First, analyses were done deterministically using all input
parameters as fixed values. Deterministic modeling always
returns the same results using the same input parameters.
Second, analyses were conducted probabilistically based
on Monte Carlo simulation using defined statistical distri-
butions of input parameters to simulate results. Proba-
bilistic modeling was used to investigate the impact of
statistical scattering of the input parameters on the model
results, which elicits the uncertainty of the results. One
thousand replicates were performed based on underlying
probability distributions for input parameters and the mean
of the costs and QALYs was calculated. Percentile confi-
dence intervals were estimated for cost and QALYs. To
estimate the percentile confidence intervals, the 2.5th and
97.5th ordered values were used as lower and upper limits
of the confidence interval, respectively.
Six hypothetical scenarios were run, for men and women
at younger (30), middle (50) and older (70) age, to describe
the cost-effectiveness of the intervention for both sexes at
different age groups. Cost and QALY differences between
no intervention and intervention, and incremental cost-ef-
fectiveness ratios (ICERs, cost per QALY gained) were
estimated and visualized in the cost-effectiveness quad-
rants (cost-effectiveness planes, CE planes) as scatterplots
of the Monte Carlo simulation results. The cost-effective-
ness acceptability curves (CEA curves) displayed the
probability that the data are consistent with a true cost-
effectiveness ratio falling below a specified threshold
value. CE planes and CEA curves were estimated for all six
Table 3 Assumed lifestyle change, effects at starting year of Markov
model, no intervention vs. intervention











Normal 71.2 As no intervention
High 28.8
Blood pressure (%)















Current snus use (%)




At least 9.2 18.3
Less than 90.8 81.7
Marital status (%)
Married 84.1 As no intervention
Single 15.9
Family history of T2D (%)
No 77.4 As no intervention
Yes 22.6
Self-perceived health (%)
Good 73.8 As no intervention
Bad 26.2
BMI body mass index, calculation: (weight in kg)/(height in m)
a ?5% from overweight with no intervention
b ?5% from obese with no intervention, –5% to normal weight
compared to no intervention
c –5% to overweight compared to no intervention
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sex-age scenarios to enhance readability of model results.
Cost-effectiveness planes and cost-effectiveness accept-
ability curves assist in reading the distribution of the
probabilistic outcomes and the probability of whether the
intervention is cost-effective assuming different threshold
values.
Distribution of probability parameters for probabilistic
analysis
A beta distribution was chosen for transition probabilities
and HUWs, since the beta distribution is appropriate for
modeling values between 0 and 1. The method of moments
was applied [39].
A gamma distribution was chosen for cost parameters. A
gamma distribution is recommended for cost estimations
since cost data are constrained to be non-negative and are
made up of counts of resource use weighted by unit costs
[39].
As no standard deviation was provided in the sources
used for the cost parameters, the mean values of the cost
estimations were assumed for the standard deviations. This
is a commonly applied assumption for the gamma distri-
bution in probabilistic analyses using the specific charac-
teristics of the gamma distribution [39].
The assumed threshold for cost-effectiveness was
50,000 € per QALY gained. This means that all interven-
tions that cost less than 50,000 € per one QALY gained
Table 4 Health utility weight by sex, age and intervention, based on population of Va¨sterbotten Intervention Program (2003–2012)
HUW No intervention Intervention
Sex/age NGT IFG IGT IFG and IGT T2D NGT IFG IGT IFG and IGT T2D
Male/30 0.83 0.82
0.73
0.77 0.72 0.83 0.82 0.73 0.77 0.72
Male/50 0.83 0.82
0.72
0.79 0.72 0.83 0.82 0.72 0.79 0.72
Male/70 0.83 0.81
0.72
0.81 0.72 0.83 0.82 0.72 0.81 0.72
Female/30 0.80 0.79
0.70
0.74 0.68 0.80 0.79 0.70 0.74 0.68
Female/50 0.80 0.79
0.70
0.76 0.68 0.80 0.79 0.70 0.76 0.68
Female/70 0.80 0.78
0.69
0.78 0.68 0.80 0.78 0.69 0.78 0.68
HUW health utility weight





IFG 3853.30 46% of T2D total cost [35–37]
IGT 3853.30 46% of T2D total cost [35–37]
IFG and
IGT
3853.30 46% of T2D total cost [35–37]
T2D 8376.74 direct (3602.00 €) ? indirect (4774.74 €) costs
Direct
costs
3602.00 Mean direct costs of T2D per patient, year 2004, year 2007, euros, including: inpatient care, outpatient hospital care;
outpatient primary care, antidiabetic drugs, antihypertensive drugs, lipid-lowering drugs, devices; SD: 9537 € [33]
Indirect
costs
4774.74 57% of total T2D cost; including: sickness absence, early retirement, production loss due to mortality [34]
NGT normal glucose state
IFG impaired fasting glucose
IGT impaired glucose state
IFG and IGT combination of IFG and IGT
T2D type 2 diabetes mellitus
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through intervention were considered as cost-effective.
This arbitrary threshold is used in other cost-effectiveness
analyses [40]. However, cost-effectiveness acceptability
curves have been presented to describe the cost-effective-
ness assuming different threshold values.
Sensitivity analyses
Sensitivity analyses were conducted in five ways:
(a) Probabilistic sensitivity analysis was performed with
Monte Carlo model simulations with 1000 replica-
tions to account for uncertainty in multiple param-
eters (probabilistic).
(b) The possibility of changing from T2D to any of the
pre-diabetic states was removed to investigate the
influence of this transition on the model results
(deterministic).
(c) The cost in states and the cost of the intervention
were varied by plus and minus 10% to investigate
the influence of the variance on cost estimates and
because cost estimates revealed greatest uncertainty
(deterministic).
(d) The time the intervention showed effect was doubled
from 7 years to 14 years to investigate whether this
lower assumpted duration of effect influenced the
results.
(e) The reduction in weight was changed from 5 to
3.3%, which corresponds to the average decreased
weight in community-based weight loss programs in
the United States (Table 2, [41]) to investigate the
influence of less optimistic effects (deterministic).
Further, the reduction in weight of 3.3% was
assumed to be the only effect (deterministic).
Results
Deterministic analyses
Running the model deterministically (stable input param-
eters) with different scenarios of age and sex showed the
effect that the intervention was more costly than no inter-
vention but also gained higher QALYs (Table 6). The
higher QALYs for the intervention group showed that the
intervention was effective compared to no intervention.
The ICER was highest for men at older age (men, age 70:
9215 € per QALY gained) and lowest for women at
younger age (women, age 30: 3833 € per QALY gained).
The ICER was more favorable for women compared to
men and for younger age compared with older age
(Table 6). All ICERs were cost-effective assuming a cost-
effectiveness threshold of 50,000 € per QALY gained.
Probabilistic analyses
Running the model probabilistically 1000 times while
assuming specified statistical distributions elicits the
uncertainty of the results. The mean cost difference was
higher than the median cost difference for all scenarios,
while the difference in effect between mean and median
values was very small (Table 7). The difference between
mean and median in cost was due to the right skewed
distribution of the data. The percentile interval for the cost
difference was large, ranging from cost-saving results to
higher cost for the intervention (Table 7). This large range
derived from the large assumed standard deviation of the
cost, i.e., standard deviation being equal to the mean value
of the costs. The ICERs derived by probabilistic analysis
were comparable to the deterministic results (Tables 6, 7).
Table 6 Cost, QALY and ICER, deterministic
Male Female
Cost QALY ICER Cost QALY ICER
Age 30
No intervention 53,915 19.9 46,037 20.1
Intervention 56,383 20.5 4109 48,355 20.7 3833
Age 50
No intervention 65,013 14.5 59,742 15.2
Intervention 67,690 14.9 6088 62,341 15.6 5656
Age 70
No intervention 44,721 7.5 47,739 8.3
Intervention 46,819 7.7 9215 49,957 8.6 8728
QALY quality adjusted life year, ICER incremental cost-effectiveness ratio, change in cost/change in effect, euros per 1 QALY gained
A. Neumann et al.
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Cost-effectiveness planes
The cost-effectiveness planes (CE planes) showed the
distribution of results according to the Monte Carlo simu-
lation of the probabilistic analyses (Fig. 2). All CE planes
indicated that the intervention almost always increased
QALYs. The intervention partly saved costs and incurred
costs; however, the range in cost difference was large as
indicated by the percentile range above (Table 7). The
spread of the incremental QALYs decreased with age.
Cost-effectiveness acceptability curves (CEA curves)
The cost-effectiveness acceptability curves (CEA curves)
showed that the probability of the intervention being cost-
effective was very high for all scenarios for the threshold
value of 50,000 € per QALY gained (Fig. 3). The proba-
bility of being cost-effective at the threshold value of
50,000 € per QALY gained ranged from 85.0% (men,
50 years) to 91.1% (men, 30 years).
Sensitivity analyses
(a) The incremental cost, QALY and ICER based on the
probabilistic results (Table 7), the CE planes (Fig. 2)
and the CEA curves (Fig. 3) indicated that the
uncertainty around the cost distribution was high.
Therefore, additional one-way sensitivity analyses
were conducted [see (c)].
(b) Not allowing the model to transit from T2D to any
pre-diabetic state influenced the ICER. While the
difference between this change and the model with
the transition was low among older people, the ICER
got less favorable with middle age and was far from
cost-effective for younger people (Table S1, Sup-
plement). Incremental QALYs between intervention
and no intervention were small for people in younger
age leading to less favorable ICERs. Comparing the
CE planes showed that the uncertainty around
incremental cost was similar to the results of the
model including the transition back from T2D
(Fig. S1, Supplement). However, the spread among
incremental QALYs was higher among younger age
in the model without the transition (Fig. S1,
Supplement).
(c) Modifying the cost in the states and the cost of the
intervention by ±10% did not have a huge impact on
the ICER (Tables S2–S5, Supplement).
(d) Doubling the time the intervention showed effect
(with linear decrease over time), which influenced
the transition probabilities and the HUWs in the
intervention, did not have a huge effect on the ICER
(Table S6, Supplement).
(e) Adjusting the assumed effect of the intervention to
lower effects in weight change (Table S7; Fig. S2,
Supplement) or lower effects in weight change and
no other effects (Table S8; Fig. S3, Supplement) did
not have a huge impact on the ICER.
Table 7 Incremental cost and quality adjusted life year (QALY), intervention vs no intervention, probabilistic, 1000 simulations
Male Female
D Cost D QALY ICER D Cost D QALY ICER
Age 30
Mean 3228 0.60 5 402 2117 0.61 3455
Median 2592 0.59 1783 0.61
Percentile interval –33,852; 41,414 0.27; 0.97 –30,122; 34,400 0.29; 0.97
Age 50
Mean 2983 0.43 6 885 2065 0.45 4552
Median 2392 0.43 1962 0.45
Percentile interval –35,499; 37,372 0.16; 0.76 –30,525; 37,260 0.12; 0.81
Age 70
Mean 2138 0.22 9 505 2192 0.25 8771
Median 1866 0.22 1 995 0.25
Percentile interval –11,322; 17,653 0.12; 0.35 –12,624; 19,436 0.13; 0.40
QALY quality adjusted life year, ICER incremental cost-effectiveness ratio




The results of this analysis showed that the described
hypothetical intervention was very cost-effective for men
and women at all ages. The cost-effectiveness planes
showed the distribution of the cost and outcomes and the
cost-effectiveness acceptability curves underlined that the
probability that the intervention was cost-effective was
high assuming a threshold value of 50,000 € per QALY
gained. Assuming that the described hypothetical inter-
vention and its effect was similar to those of the DPS, this
analysis showed what would happen if a DPS-like inter-
vention were implemented in Va¨sterbotten.
Other studies
Several studies have estimated the cost-effectiveness of
lifestyle intervention. However, none focused on the costs
and effects of NGT, IFG, IGT, and IFG and IGT on the





Fig. 2 Cost-effectiveness planes by age [younger (30), middle (50), older (70)] and sex (male, female), 1000 simulations
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the results of different cost-effectiveness studies with each
other as methods, health care systems, costs included,
perspectives, lifestyle interventions and other factors differ
[13]. Nonetheless, in the following, the results of this study
were compared with other modeling studies focusing on
T2D prevention through lifestyle change.
Similar lifestyle interventions for preventing T2D were
also cost-effective [14, 15, 19, 20, 42], cost-saving
[16–18, 21, 43, 44] or had mixed results [45].
A Markov Monte Carlo simulation on the cost-effec-
tiveness of screening for T2D found that early detection
and prevention of T2D by either lifestyle intervention or
metformin may be cost-effective, with 562.54 € per QALY
for lifestyle intervention [19]. Forster and colleagues ana-
lyzed the cost-effectiveness of two diet and exercise
interventions, showing that those interventions have the
potential to be cost-effective [42]. Smith and colleagues





Fig. 3 Cost-effectiveness acceptability curves by age [younger (30), middle (50), older (70)] and sex (male, female)
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$20,000 per QALY gained in approximately 78% and less
than $50,000 per QALY gained in approximately 86% of
model iterations using cost-effectiveness acceptability
curves [14]. An estimation of the cost-effectiveness of the
DPP showed that the intervention could provide a financial
return on investment for private payers and long-term
benefits for Medicare with an estimated cost of $1288 per
QALY gained at age 50 [15]. A modeling study based on
an example from Germany estimated that lifestyle inter-
ventions for primary prevention of T2D have a high
potential to be cost-effective [20].
In a modeling study examining the effect of lifestyle
intervention for preventing T2D in an Australian setting,
the program was dominant over no treatment (cost- and
life-saving) [21]. Ha¨ussler and Breyer estimated that a
German lifestyle intervention to reduce obesity among
obese people without increased glucose tolerance can pay
for itself from the point of view of a health insurer [43].
The evaluation of the European Community-based project
‘‘10,000 Steps Ghent’’ showed that the intervention, which
focused on increased physical activity, was dominant
compared to no intervention [44]. A cost-effectiveness
evaluation of the Diabetes Prevention Program Outcomes
Study estimated that lifestyle intervention among people
with pre-diabetes produces long-term social benefits which
exceed intervention costs [16]. A simulation model based
on Swedish data estimated that lifestyle intervention pro-
grams save a mean total of 1853 € per patient [17]. Liu and
colleagues estimated that programs to prevent T2D using
lifestyle interventions were cost-saving in a Chinese setting
[18].
Strengths and weaknesses
This study has several strengths. Both the health utility
weight and the risk equations that define the transition
probabilities were estimated from the same source, the
Va¨sterbotten Intervention Program (VIP) and for NGT,
IFG, IGT, and T2D. As other studies only included IGT
instead of IFG and IGT, and very few studies considered
NGT, this analysis provides essential information on the
prevention of T2D and its pre-states. Several sensitivity
analyses including probabilistic sensitivity analysis enable
the reader to judge the soundness of the model and its input
parameters. In addition, CEA curves and CE planes assist
the reader in judging the stability of the results and the
change with assumed threshold value.
On the other hand, some limitations are to be mentioned.
As the focus of this study was the prevention of T2D, this
model did not differentiate between T2D with and without
complications. However, neither complications nor pre-
vention of complications were in the focus of this analysis.
Hypothetical persons who just entered the T2D state would
be underestimated in HUW and overestimated in cost
terms. Over time, the complications increase and the cost
increases, while the HUWs decrease. Hypothetical persons
who were in T2D for a long time would be underestimated
in cost estimates and overestimated in HUWs in this
model. However, as a lifetime time horizon was used here,
these differences disappear or are marginal since some-
times over- and sometimes underestimations would bal-
ance using the average value. In addition, due to the lack of
information on cost of IFG compared to IGT, the cost
within the pre-diabetic states was assumed to be the same.
Further, data for transition probabilities and health utility
weights for T2D with or without complications were not
available. However, it has to be kept in mind that the cost
of T2D is strongly associated with complications, while the
combination of micro- and macrovascular complications
incurs the highest cost [45, 46]. Further, as the population
of inhabitants in Va¨sterbotten is fairly small (approxi-
mately 260,000), the robustness of the mortality values
could be questioned. However, cross-checking the mor-
tality in Va¨sterbotten with the mortality in entire Sweden
showed no significant difference. As input parameters for
the model were taken from different sources, this could
limit the internal validity of the model. However, it was
impossible to extract all necessary information for the
model from the same source. Nevertheless, most data were
taken from the Va¨sterbotten population or the Diabetes
Prevention Study in Finland. In addition, the internal
validity of the model could be reduced as different studies
were used to describe the effect of the intervention. Fur-
ther, IGT was associated with lower HUWs compared to
IFG and IGT (Table 4), which seems counter-intuitive.
Having IGT in the described risk profile (Table 3) seems to
reveal worse HUWs for IGT compared to IFG and IGT.
Nonetheless, the HUWs of all pre-diabetic states ranged
between NGT and T2D and the differences were too small
to have huge impacts on the final results.
Importance of assumptions and model structure
All models are based on a certain number of assumptions,
as not all data are available. Some assumptions in this
model were based on data of the VIP and some assump-
tions on results from other studies. The main assumptions
were: the cost of all pre-diabetic states was the same and
was 46% of those of T2D; the development of pre-diabetic
states after T2D was possible; the effect of the intervention
only lasted for 7 years, with a linear decrease over time;
the effect of lifestyle change was according to the Diabetes
Prevention Study; there was no increased risk of dying due
to pre-diabetic states; the chosen statistical distributions for
the probabilistic estimations were used; and the standard
deviation equaled the mean cost. The lack of data is indeed
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one of the reasons modeling is needed. It is recognized that
modeling studies are valuable in the decision-making
process where real-life data or intervention effectiveness is
insufficient or absent [21]. Therefore, informed and well-
guided assumptions need to be made for decision-making.
This analysis has shown that model structure is an
important issue of modeling. The possible transition
between T2D and any pre-diabetic state could be argued.
Markov models ignore information on what has happened
in the cycles before and, therefore, do not differentiate in
any pre-diabetic state between those who moved from T2D
to a pre-diabetic state and those in the pre-diabetic state
who never had T2D. On the other hand, this transition is
technically and physiologically possible and, due to the
limitation that this model does not differentiate between
less severe T2D and T2D with complications, it allows
separation of those people with low-profile T2D from those
in more severe states. It was decided to keep this transition,
as it is plausible and underlines the dynamics in the model,
and to have its influence checked in a sensitivity analysis.
The sensitivity analysis showed that this assumption does
have a large impact on the result.
Clinical trials have largely targeted IGT, while also
other trials have shown that prevention in individuals with
IFG can be effective [47]. The effectiveness in our model,
i.e., influence on weight, physical activity and diet, was
also taken from clinical trials, which only included IGT as
the pre-diabetic state. However, the results of the effec-
tiveness in our model were translated to effects based on
risk equations for transition probabilities [22] and health
utility weights [23]. Therefore, the influence of IFG, IGT,
and IFG and IGT were modeled separately based on dis-
tinct functions.
Possible transitions between the pre-diabetic states were
not modeled, as the population used in the model was too
small to lead to robust estimates. On the other hand, such
transitions would not have a huge impact on the outcome of
the model as both the effect (HUWs) and the costs were
very similar between pre-diabetic states.
Even though QALYs gained were low, other benefits that
derive from the intervention should not be omitted.
Prevention of pre-diabetic conditions and T2D as well as the
adoption of a healthy lifestyle also have positive impacts on
other diseases such as cardiovascular diseases and some
cancers. Therefore, the positive effect in terms of prevention
of cost due to cardiovascular diseases and cancer of this
model is, therefore, likely to be underestimated.
The intervention was assumed to only have effects on
BMI, nutrition and physical activity, and only last for
7 years with a linear decrease. For some people, lifestyle
intervention programs could have a longer lasting effect
than just 7 years. The Chinese Da Qing study, for example,
showed an effectiveness of lifestyle intervention even after
20 years [48]. However, sensitivity analyses have shown
that doubling the duration of time of the intervention
showed a small impact on the results, which can be
explained by the highest difference in effect between
intervention and no intervention being in the 1st year and
thereafter decreasing substantially within a few years.
Implications for policy makers
This analysis aimed to provide indicators for long-term
allocation of healthcare resources in Sweden and other
European countries. In linewith other studies, the prevention
of T2D through lifestyle change can be very cost-effective.
Targeting weight reduction through increase of physical
activity and change in diet would have a strong implication
on future T2D risk. The return on investment in T2D pre-
vention initiatives in a group setting is high. This analysis
shows that implementing a DPS-like intervention in
Va¨sterbotten would have a high potential to be cost-
effective.
However, one has to be aware that targeting the T2D
epidemic only at individual level may likely not suffice.
Interventions and actions at policy and environmental level
need to supplement individual interventions for a sustain-
able reduction in T2D incidence [49]. The rising incidence
is driven by a wide mix of factors at different levels, such
as individual susceptibility, food supply, transportation use,
climate change or the economic situation of the country
[50]. Targeting individual interventions is one important
step towards slowing the progression of T2D but should not
be the only initiative.
Conclusion
The prevention or the delay of the onset of T2D is feasible
and cost-effective. A small investment in healthy lifestyle
with change in physical activity and diet together with
weight loss are very likely to be cost-effective. Having a
lifestyle intervention comparable to DPS implemented in
the north of Sweden has a high potential to be effective and
cost-effective.
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